Non-tyrosine kinase inhibitor (TKI)-targeting of BCR-ABL expressing cells.
Summary of "Non-tyrosine kinase inhibitor (TKI)-targeting of BCR-ABL expressing cells."
No Summary Available
Affiliation
Journal Details
This article was published in the following journal.
Name: Leukemia & lymphoma
ISSN: 1029-2403
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22568509
- DOI: http://dx.doi.org/10.3109/10428194.2012.692089
Medical and Biotech [MESH] Definitions
Cyclin-dependent Kinase Inhibitor P27
A cyclin-dependent kinase inhibitor that coordinates the activation of CYCLIN and CYCLIN-DEPENDENT KINASES during the CELL CYCLE. It interacts with active CYCLIN D complexed to CYCLIN-DEPENDENT KINASE 4 in proliferating cells, while in arrested cells it binds and inhibits CYCLIN E complexed to CYCLIN-DEPENDENT KINASE 2.
Protein Kinase C-epsilon
A protein kinase C subtype that was originally characterized as a CALCIUM-independent, serine-threonine kinase that is activated by PHORBOL ESTERS and DIACYLGLYCEROLS. It is targeted to specific cellular compartments in response to extracellular signals that activate G-PROTEIN-COUPLED RECEPTORS; TYROSINE KINASE RECEPTORS; and intracellular protein tyrosine kinase.
Receptor, Ephb6
An eph family receptor found primarily in BRAIN and THYMUS. The EphB6 receptor is unusual in that its tyrosine kinase domain shares little homology with other members of this class. The unusual tyrosine kinase domain of this receptor appears to result in its lack of tyrosine kinase activity.
Fms-like Tyrosine Kinase 3
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Proto-oncogene Proteins C-kit
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
PubMed Articles
BACKGROUND: Src tyrosine kinase and matrix metalloproteinase play the pivotal roles in lung cancer invasion and metastasis. The aim of this study is to evaluate the effect of Src tyrosine kinase inhib...
The tyrosine kinase Fyn is a member of the Src family kinases which are important in many integrin-mediated cellular processes including cell adhesion and migration. Fyn has multiple phosphorylation s...
Activation of the TASK-2 channel after cell swelling is dependent on tyrosine phosphorylation.
The swelling-activated K(+) currents (I(K,vol) ) has in Ehrlich Ascites Tumour Cell (EATC) been reported to be through the two-pore domain (K(2p)), acid sensitive K(+) channel TASK-2. The regulatory v...
Flavonoids as receptor tyrosine kinase FLT3 inhibitors.
The Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase, is involved in the proliferation, differentiation and apoptosis of hematopoietic cells. FLT3 is highly overexpressed in acute myeloid...
Store-operated calcium entry(SOCE) is essential for many cellular processes. In this study we investigated modulation of SOCE by tyrosine phosphorylation in rat epididymal basal cells. The intracellul...
Clinical Trials
A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates...
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effectiv...
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-recepto...
To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the tr...
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal serou...
